Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

Clinical trial NCT01897571 · COMPLETED

Trial details

NCT number: NCT01897571
Sponsor: Epizyme, Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

B-cell Lymphomas (Phase 1)Advanced Solid Tumors (Phase 1)Diffuse Large B-cell Lymphoma (Phase 2)Follicular Lymphoma (Phase 2)Transformed Follicular Lymphoma Primary Mediastinal Large B-Cell Lymphoma

Start date: 2013-06-13
Primary completion: 2021-08-24
Enrollment: 400

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.